The study is carried out over short treatment periods. Participants receive NHS7108 or Zenpep by mouth, and the treatments are compared in a crossover design, which means the same person may receive more than one study treatment at different times. During the study, health checks are done to look for side effects and changes in routine medical tests, heart tracing, and physical examination findings. The study also looks at how well food is digested and at changes in stomach and bowel symptoms, including stool frequency and stool consistency.

The main focus is on different doses of NHS7108 taken daily for 14 days. The study compares these doses with Zenpep and follows changes in digestion-related measures such as nitrogen absorption, which shows how well protein from food is being taken up by the body, and fat absorption. It also checks levels of certain fats in the blood after a meal and records digestive symptoms over time.

The purpose of this study is to evaluate how Creon affects the nutritional status of patients with PEI following their surgery. Participants in the study will take Creon capsules orally. The study will monitor the patients over a period to see if their nutritional status remains stable, particularly looking at whether there is any loss of body weight from the start of the study. Other aspects being observed include changes in body weight, symptoms of PEI, nutritional parameters, and overall quality of life related to gastrointestinal health.

Throughout the study, participants will be asked to keep diaries to record any symptoms they experience. The study will also track any side effects that may arise from the treatment, as well as changes in vital signs. The goal is to gather information on how effective Creon is in managing the symptoms of PEI and maintaining the nutritional health of patients who have had a total gastrectomy.

The purpose of the study is to understand how many patients need doses higher than 70,000 units of Creon® per main meal to manage their condition effectively. Participants will take the medication orally in the form of gastro-resistant capsules, which are designed to withstand stomach acid and release the enzymes in the intestines where they are needed. The study will monitor various aspects of the participants’ health, including their nutritional status, body weight, and quality of life, as well as any side effects related to the treatment.

Throughout the study, participants will keep a diary to record their symptoms, such as abdominal pain and changes in stool frequency and consistency. The study aims to provide valuable information on the effectiveness and safety of Creon® for managing PEI after pancreatic surgery, helping to improve treatment strategies for patients with this condition.

The purpose of the study is to evaluate whether PERT can help patients with pancreatic cancer gain weight and improve their overall health and quality of life. Participants in the study will be randomly assigned to receive either the PERT treatment or a placebo. The study will last for six months, during which time participants will have regular check-ups to monitor their weight, nutritional status, and overall health. The study aims to see if PERT can lead to weight gain, better nutrition, and improved tolerance to chemotherapy, which may ultimately enhance the quality of life and survival for these patients.

Throughout the study, various health markers will be monitored, including changes in blood components like haemoglobin and lymphocytes, as well as nutritional markers such as albumin and cholesterol. The study will also assess changes in symptoms related to digestion, such as diarrhea and abdominal discomfort, and evaluate the participants’ quality of life using a specific questionnaire. The results will help determine if PERT is beneficial for patients with pancreatic cancer who are experiencing pancreatic exocrine insufficiency.